STERIS plc (STE) FY2025 Earnings Quality Report

Grade: F — Major red flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Fiscal year ended March 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Unqualified opinion (1 critical audit matter: Uncertain Tax Positions)

One-line verdict: STERIS earns an F because two checks fail: cash of $172M covers only 8% of the $2.2B debt load (C4 critical fail), and goodwill plus intangibles equal 90% of equity (D1 fail). The underlying business is healthy — revenue grew 6.2% to $5.46B, gross margin expanded 80bp to 44.0%, operating cash flow rose to $1.15B, and the company used most of the $787.5M Dental segment divestiture proceeds to pay down $1.2B of long-term debt (debt fell from $3.38B to $2.20B). EY's sole critical audit matter is a $50M IRS notice-of-deficiency dispute related to FY2018 deemed dividend withholding tax — a technical tax matter, not an operational one. The F grade is a mechanical consequence of the still-heavy acquired-goodwill base and the thin operating cash buffer.

Sterilization and Infection Prevention Leader

STERIS describes itself in the MD&A as "a leading global provider of products and services that support patient care with an emphasis on infection prevention." The company operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. A fourth Dental segment was divested effective May 31, 2024 for $787.5M total cash consideration and is presented as discontinued operations.

The product mix spans consumables (detergents, endoscopy accessories, barrier products, instruments), services (equipment maintenance, microbial reduction, instrument repair, outsourced reprocessing, laboratory testing), and capital equipment (sterilizers, surgical tables, automated endoscope reprocessors).

From the MD&A: "Revenues increased $320.8 million, or 6.2%, to $5,459.5 million for the year ended March 31, 2025, as compared to $5,138.7 million for the year ended March 31, 2024."

From the MD&A: "Our gross profit percentage increased to 44.0% for fiscal 2025 as compared to 43.2% for fiscal 2024. Favorable impacts from pricing, mix, productivity, and material costs were partially offset by unfavorable impacts from labor and overhead costs."

Recent Acquisitions and Divestitures

The FY2025 10-K discloses significant portfolio activity. From the MD&A:

Cash Flow: Very Strong

From the MD&A: "Cash flows provided by operating activities were $1,148.1 million and free cash flow was $787.2 million in fiscal 2025 compared to cash flows provided by operating activities of $973.3 million and free cash flow of $620.3 million in fiscal 2024."

The FY2025 operating cash flow improvement is attributed specifically to working capital improvement. Per the MD&A: "The fiscal 2025 increase in cash flows from operations and free cash flow resulted from the increase in cash provided by working capital, primarily driven by higher collections on accounts receivable and improved inventory management when compared to the prior year."

CFFO/NI of 1.87 is excellent. The C1 check passes with room. Free cash flow of $778M is available for dividend payments ($222M annually at $0.57 per share), continued bolt-on M&A, and further debt reduction.

The Balance Sheet: Post-Dental-Sale Deleveraging

The debt reduction from $3.38B to $2.20B is the single most important balance sheet change. The proceeds of the Dental divestiture ($787.5M) plus the CECS sale ($41.9M) plus retained cash flow funded a $1.18B long-term debt paydown. Debt-to-total-capital ratio is now 23.6% per the MD&A — a healthy level.

Cash of $172M is very thin against the remaining $2.2B debt (C4 fail at 8% coverage). STERIS operates on a low-cash operating model, relying on its $1.15B annual operating cash flow to service obligations.

Goodwill of $4.10B plus intangibles of $1.85B equals $5.95B — 90% of the $6.62B total equity (D1 fail). Most of this is from legacy acquisitions: the 2015 Synergy Health acquisition ($1.9B), the 2021 Cantel Medical acquisition ($4.6B, which included the Dental business that has now been divested), and the BD surgical assets deal.

The 18-Point Screening

Revenue Quality

Revenue quality is clean. DSO improved by 2 days. AR grew 3.5% vs. revenue growth of 6.2% — receivables growing slower than sales is a positive sign. CFFO grew 18% against revenue growth of 6.2%, confirming the revenue was translated into cash.

Expense Quality

B1: Inventory *declined* 13.8% while COGS grew 4.7% — the opposite of a stockpiling concern. The MD&A confirms this is deliberate improvement in inventory management ("improved inventory management when compared to the prior year").

B4: Gross margin expansion of 80bp reflects pricing power and mix improvement.

Cash Flow Quality

C4 (critical fail): The lowest cash coverage ratio in this cohort — just 8%. STERIS holds $172M in cash, reflecting its preference to deploy cash into debt paydown and dividends rather than balance sheet buffers. With $1.15B annual CFFO, interest coverage is strong, but the raw cash-to-debt ratio triggers the fail.

Balance Sheet

D1 (fail): Goodwill + intangibles at 90% of equity reflects the debt-financed Synergy, Cantel, and BD acquisitions over the past decade. After the Dental divestiture, the intangibles line fell from $2.12B to $1.85B (disposal of Dental-related intangibles), but goodwill was essentially unchanged at $4.10B. The ratio remains above the 50% threshold.

D2: Debt/EBITDA of 1.6x passes comfortably — the post-divestiture deleveraging improved this materially. STERIS is not in leverage distress despite the D1 fail.

D3 (watch): Other assets grew 25.4%. This reflects the capital investment in the AST business (Applied Sterilization Technologies requires significant gamma irradiation facilities) and PP&E growth from $1.77B to $1.96B.

M&A Risk

E2 passes because the total intangibles line actually declined, reflecting the Dental disposal.

Beneish M-Score

M-Score of -2.62 is comfortably below threshold — among the cleanest in this cohort. The combination of clean accruals, stable DSO, stable SG&A ratio, and gross margin expansion all contribute to the clean reading.

Critical Audit Matter: Uncertain Tax Positions

EY identified a single critical audit matter relating to IRS notices of deficiency. From the audit report:

"As discussed in Note 10 to the consolidated financial statements, the Company received two notices of deficiency from the U.S. Internal Revenue Service (the IRS) regarding deemed dividend inclusions and associated withholding tax for fiscal year 2018. The IRS adjustments would result in a cumulative tax liability of approximately $50 million. The Company believes it is more-likely-than-not that they will be able to sustain the tax benefit recognized in the U.S. and has not recorded a liability for an uncertain tax position related to this matter."

The matter is complex: "Auditing management's analysis of tax positions related to the lack of deemed dividend inclusions and associated withholding tax was challenging as the analysis is highly judgmental due to complex interpretations of tax laws and legal rulings."

EY's procedures included "involving income tax subject matter resources to assess the technical merits of the Company's tax positions related to the deemed dividend inclusions and associated withholding tax. We assessed the Company's correspondence with the relevant tax authorities and evaluated income tax opinions and other third-party advice obtained by the Company."

The $50M potential liability is material relative to annual net income (~8% of FY2025 net income) but manageable in absolute terms. STERIS did not record any reserve because management and EY concluded the position is more-likely-than-not to be sustained. The matter dates to STERIS plc's 2015 Irish re-domicile and the associated inter-company dividend structure — the type of international tax position that the IRS routinely challenges after the fact.

EY has served as STERIS's auditor since 1989.

Key Risks from Item 1A

1. International trade and tariff policy. From Item 1A: "The U.S. and other countries have announced changes, and planned changes, to international trade policy, including increasing tariffs on imports, and potentially renegotiating or terminating existing trade agreements. The international trade environment is highly dynamic, and such changes, and retaliatory responses thereto, continue to evolve."

2. Healthcare reimbursement pressure. From Item 1A: "We sell many of our products and services to hospitals and other healthcare providers and pharmaceutical manufacturers. Many of these Customers are subject to or supported by government programs or receive reimbursement for services from third-party payors... Government or other third-party payors may deny or change coverage, reduce their current levels of reimbursement for healthcare services."

3. Product recall and regulatory compliance. From Item 1A: "Our products are subject to recalls and restrictions, even after receiving U.S. or foreign regulatory clearance or approval. Ongoing medical device reporting regulations require that we report to appropriate governmental authorities in the U.S. and/or other countries when our products cause or contribute to a death or serious injury or malfunction."

4. Ethylene Oxide (EO) litigation. The MD&A acknowledges: "increased volume and pricing, which was partially offset by legal costs and a settlement associated with our EO litigation." STERIS operates gamma and EO sterilization facilities; EO emissions litigation has affected the AST segment and peer companies (Sterigenics, etc.).

5. Product liability and legal actions. Item 1A explicitly lists the potential actions the company might face: "warning letters, fines, civil penalties, criminal penalties, loss of tax benefits, injunctions, product seizure, recalls, suspensions or restrictions, re-labeling, detention, and/or debarment."

6. FCPA and anti-corruption. From Item 1A: "We are subject to compliance with various laws and regulations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and similar anti-bribery laws... we cannot assure you that our internal policies and procedures will always protect us from violations of these laws."

Altman Z-Score and F-Score

Z-Score of 3.98 comfortably clears safe-zone thresholds. The F-Score of 0.47 is among the lowest in our med-device coverage — reflecting the clean accruals, lack of suspicious goodwill growth, and disciplined cash flow pattern.

Summary

Grade: F. Two fails (C4 critical and D1) drive the grade.

STERIS's F grade is driven entirely by the two balance sheet fails. The underlying business is performing well: revenue +6.2%, gross margin expanding, operating cash flow +18% to $1.15B, Dental divestiture successfully completed, $1.2B of long-term debt paid down, and an M-Score of -2.62 that is comfortably clean. EY issued an unqualified opinion and the single critical audit matter is a $50M IRS tax dispute that is more-likely-than-not to be sustained.

C4 (cash vs. debt): The 8% coverage ratio is the lowest in this cohort. STERIS deliberately runs with minimal cash and services debt from $1.15B of annual operating cash flow. Debt/EBITDA of 1.6x is the healthier measure and it passes.

D1 (goodwill + intangibles): At 90% of equity, this reflects the legacy Synergy Health, Cantel Medical, and BD acquisitions. After the Dental divestiture, intangibles declined to $1.85B but goodwill of $4.10B is unchanged.

The real business risks are EO sterilization litigation (referenced in the MD&A), healthcare reimbursement pressure, and the ongoing $50M IRS dispute. None of these are accounting-quality concerns. The two fails are mechanical consequences of STERIS's acquisition-driven growth strategy over the past decade, combined with a capital structure that prioritizes debt paydown and dividends over cash buffers.

**Disclaimer**: This report is based on STERIS's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Fiscal year ended March 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP (Unqualified opinion, 1 critical audit matter: Uncertain Tax Positions)